Skip to main content
KAINOS MEDICINE, INC. logo

KAINOS MEDICINE, INC. — Investor Relations & Filings

Ticker · 284620 ISIN · KR7284620002 KO Professional, scientific and technical activities
Open in API
Filings indexed 375 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 284620

About KAINOS MEDICINE, INC.

http://kainosmedicine.com

Kainos Medicine, Inc. is a clinical-stage research and development company specializing in the discovery of novel small molecule therapeutics. The company's primary focus is on addressing unmet medical needs in neurodegenerative disorders, infectious diseases, and oncology. Its drug pipeline includes candidates for the treatment of conditions such as Parkinson's disease, Multiple System Atrophy (MSA), AIDS, and various cancers. Kainos Medicine is dedicated to developing innovative treatments for these challenging diseases.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is a Korean "분기보고서" (Quarterly Report) for the 10th term covering the period January 1, 2026 to March 31, 2026, containing detailed financial data, capital changes, stock schedules, business description, management changes, and other substantive content typical of an interim/quarterly financial report rather than a simple announcement or summary. This aligns with the definition of an Interim / Quarterly Report (Code: IR). Q1 2026
2026-05-15 Korean
[기재정정]단일판매ㆍ공급계약체결
Regulatory Filings
2026-04-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is headed “정기주주총회 결과” (Results of the Annual General Meeting) and lists each agenda item with voting percentages, approval status, and director appointment details. It clearly provides the official outcomes of shareholder votes at the AGM. This matches the “Declaration of Voting Results & Voting Rights Announcements” category.
2026-03-31 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 91% confidence The document is a regulatory notification to the Financial Services Commission and Korea Exchange about the reappointment (appointment/dismissal) of an outside director (사외이사) at (주)카이노스메드. It details the date of change, number of directors before and after, and biographical details of the reappointed outside director. This clearly matches a Board/Management Information filing, as it announces changes in the company's board of directors.
2026-03-31 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 95% confidence The document is titled 감사보고서 (Audit Report) and contains the independent auditor’s opinion, full financial statements (balance sheet, income statement, cash flow, equity movements) and explanatory notes. It is a standalone audit report (with applied accounting policies and auditor’s emphasis paragraphs) rather than an annual management discussion or investor presentation. Therefore, it fits the Audit Report/Information category. FY 2025
2026-03-23 Korean
기타시장안내 ('25사업연도 감사의견 거절 관련 상장폐지 절차 미진행)
Delisting Announcement Classification · 95% confidence The document is a formal notice from the company about its delisting status on the KOSDAQ market due to an auditor’s disclaimer of opinion, referencing relevant KOSDAQ listing rules and the suspension of the delisting procedure. This falls squarely under an official delisting announcement.
2026-03-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.